LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $8.04 Consensus Target Price from Brokerages

LifeStance Health Group, Inc. (NASDAQ:LFST – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $8.04.

Separately, TD Cowen downgraded LifeStance Health Group from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $8.00 to $9.00 in a research note on Monday.

LifeStance Health Group Stock Performance

Shares of NASDAQ LFST opened at $8.21 on Monday. LifeStance Health Group has a 12-month low of $4.22 and a 12-month high of $10.50. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -15.79 and a beta of 0.88. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $7.52 and a 200 day moving average of $6.08.

LifeStance Health Group (NASDAQ:LFST – Get Rating) last issued its quarterly earnings data on Wednesday, May 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. LifeStance Health Group had a negative net margin of 20.63% and a negative return on equity of 12.32%. The firm had revenue of $252.59 million during the quarter, compared to the consensus estimate of $246.04 million. On average, research analysts anticipate that LifeStance Health Group will post -0.29 earnings per share for the current year.

Insider Activity at LifeStance Health Group

In related news, insider Kevin Michael Mullins sold 122,295 shares of the firm’s stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $6.12, for a total transaction of $748,445.40. Following the completion of the transaction, the insider now directly owns 5,654,552 shares of the company’s stock, valued at $34,605,858.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 264,066 shares of company stock valued at $1,744,368. 8.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On LifeStance Health Group

Several institutional investors have recently added to or reduced their stakes in LFST. OLD National Bancorp IN bought a new position in shares of LifeStance Health Group during the 4th quarter valued at approximately $49,000. Ameritas Investment Partners Inc. lifted its position in LifeStance Health Group by 56.6% during the first quarter. Ameritas Investment Partners Inc. now owns 5,575 shares of the company’s stock valued at $56,000 after purchasing an additional 2,016 shares during the last quarter. Dynamic Advisor Solutions LLC bought a new position in LifeStance Health Group during the fourth quarter valued at $56,000. Squarepoint Ops LLC purchased a new position in shares of LifeStance Health Group in the 4th quarter worth $62,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of LifeStance Health Group in the 2nd quarter worth about $63,000. Hedge funds and other institutional investors own 76.49% of the company’s stock.

About LifeStance Health Group

(Get Rating)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.